BNP Paribas Financial Markets Has $63,000 Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ)

BNP Paribas Financial Markets lessened its holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ) by 83.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,648 shares of the company’s stock after selling 13,822 shares during the quarter. BNP Paribas Financial Markets’ holdings in LENZ Therapeutics were worth $63,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of LENZ. Charles Schwab Investment Management Inc. lifted its position in shares of LENZ Therapeutics by 197.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 123,371 shares of the company’s stock worth $2,929,000 after buying an additional 81,901 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new position in LENZ Therapeutics during the third quarter worth about $743,000. Bank of New York Mellon Corp lifted its holdings in shares of LENZ Therapeutics by 255.4% in the second quarter. Bank of New York Mellon Corp now owns 39,737 shares of the company’s stock worth $687,000 after acquiring an additional 28,556 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of LENZ Therapeutics in the 2nd quarter valued at approximately $390,000. Finally, BBR Partners LLC bought a new stake in shares of LENZ Therapeutics during the 2nd quarter valued at approximately $346,000. Institutional investors own 54.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on LENZ shares. HC Wainwright reissued a “buy” rating and issued a $38.00 price objective on shares of LENZ Therapeutics in a research note on Thursday, November 7th. William Blair upgraded LENZ Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Finally, Raymond James assumed coverage on LENZ Therapeutics in a research report on Friday, September 27th. They set an “outperform” rating and a $37.00 price objective on the stock. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $35.40.

LENZ Therapeutics Trading Up 3.6 %

Shares of NASDAQ:LENZ opened at $30.28 on Friday. LENZ Therapeutics, Inc. has a 52 week low of $14.42 and a 52 week high of $38.93. The firm’s fifty day moving average is $31.60 and its 200-day moving average is $24.87.

LENZ Therapeutics (NASDAQ:LENZ) last announced its earnings results on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.09. During the same period last year, the company earned ($1.33) EPS. As a group, equities analysts expect that LENZ Therapeutics, Inc. will post -2.09 earnings per share for the current fiscal year.

LENZ Therapeutics Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.